Efficacy and tolerability of immunoregulators and antibiotics in fistulizing crohn's disease: A systematic review and meta-analysis of placebo-controlled trials

Current Pharmaceutical Design

Volumn 16, Issue 33, 2010, Pages 3684-3698

  Nikfar, Shekoufeh ^a,b   Mirfazaelian, Hadi ^c   Abdollahi, Mohammad ^c  

^a TEHRAN UNIVERSITY OF MEDICAL SCIENCES   (Iran)

^b MINISTRY OF HEALTH AND MEDICAL EDUCATION   (Iran)

^c TEHRAN UNIVERSITY OF MEDICAL SCIENCES   (Iran)

Author keywords

Adverse effects; Antibiotic; Crohn's disease; Fistula; Immunoregulators; Inflammatory bowel disease; Meta analysis; Systematic review

Indexed keywords

ADALIMUMAB; AMINOSALICYLIC ACID DERIVATIVE; ANTIBIOTIC AGENT; AST 120; AZATHIOPRINE; BALSALAZIDE; BUDESONIDE; CIPROFLOXACIN; CORTICOSTEROID; DIPHENOXYLATE; IMMUNOMODULATING AGENT; INFLIXIMAB; LOPERAMIDE; MERCAPTOPURINE; MESALAZINE; METHOTREXATE; METRONIDAZOLE; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; OLSALAZINE; OPIATE DERIVATIVE; PLACEBO; PREDNISONE; RECOMBINANT GRANULOCYTE MACROPHAGE COLONY STIMULATING FACTOR; SALAZOSULFAPYRIDINE; STEROID; TACROLIMUS; TRANSFORMING GROWTH FACTOR BETA; TUMOR NECROSIS FACTOR ALPHA; TUMOR NECROSIS FACTOR INHIBITOR; UNINDEXED DRUG; ANTIINFECTIVE AGENT; GASTROINTESTINAL AGENT; IMMUNOLOGIC FACTOR; NONSTEROID ANTIINFLAMMATORY AGENT;

ABSCESS; ANTIBIOTIC THERAPY; ANUS DISEASE; ANUS FISTULA; ARTHRALGIA; ARTHRITIS; ARTICLE; CHILL; CROHN DISEASE; CYSTOCOLIC FISTULA; DIGESTIVE SYSTEM FISTULA; DISEASE EXACERBATION; DRUG EFFICACY; DRUG HYPERSENSITIVITY; DRUG SAFETY; DRUG TOLERABILITY; DRUG WITHDRAWAL; ENTEROCUTANEOUS FISTULA; ERYTHEMA; FEVER; FISTULIZING CROHN DISEASE; FURUNCULOSIS; HUMAN; ILEUS; INTENTION TO TREAT ANALYSIS; INTESTINE FISTULA; INTESTINE OBSTRUCTION; META ANALYSIS; PERIANAL ABSCESS; PERIANAL PAIN; PERIANAL SWELLING; PNEUMONIA; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL (TOPIC); RECTOVAGINAL FISTULA; RECTUM FISTULA; RISK FACTOR; SKIN BURNING SENSATION; SYSTEMATIC REVIEW; THORAX PAIN; TREATMENT OUTCOME; TREATMENT RESPONSE; UNSPECIFIED SIDE EFFECT; URETER OBSTRUCTION; GASTROENTERITIS; PATHOPHYSIOLOGY; REVIEW;

ANTI-BACTERIAL AGENTS; ANTI-INFECTIVE AGENTS; ANTI-INFLAMMATORY AGENTS, NON-STEROIDAL; CROHN DISEASE; DIGESTIVE SYSTEM FISTULA; GASTROENTERITIS; GASTROINTESTINAL AGENTS; HUMANS; IMMUNOLOGIC FACTORS;

EID: 79955695214     PISSN: 13816128     EISSN: 18734286     Source Type: Journal    
DOI: 10.2174/138161210794079236     Document Type: Article

References (38)

1. Targan SR, Hanauer SB, van Deventer SJ, et al. A short-term study of chimeric monoclonal antibody cA2 to tumor necrosis factor alpha for Crohn's disease. Crohn's Disease cA2 Study Group. N Engl J Med 1997; 337(15): 1029-35.
2. Rezaie A, Parker RD, Abdollahi M. Oxidative stress and pathogenesis of inflammatory bowel disease: an epiphenomenon or the cause? Dig Dis Sci 2007; 52(9): 2015-21.
3. Fukuda Y, Takazoe M, Sugita A, et al. Oral spherical adsorptive carbon for the treatment of intractable anal fistulas in Crohn's disease: a multicenter, randomized, double-blind, placebo-controlled trial. Am J Gastroenterol 2008; 103(7): 1721-9.
4. Lapidus A, Bernell O, Hellers G, et al. Clinical course of colorectal Crohn's disease: a 35-year follow-up study of 507 patients. Gastroenterology 1998; 114(6): 1151-60.
5. Gelbmann CM, Rogler G, Gross V, et al. Prior bowel resections, perianal disease, and a high initial Crohn's disease activity index are associated with corticosteroid resistance in active Crohn's disease. Am J Gastroenterol 2002; 97(6): 1438-45.
6. Beaugerie L, Seksik P, Nion-Larmurier I, et al. Predictors of Crohn's disease. Gastroenterology 2006; 130(3): 650-6.
7. Schwartz DA, Pemberton JH, Sandborn WJ. Diagnosis and treatment of perianal fistulas in Crohn's disease. Ann Intern Med 2001; 135: 906-18.
8. West RL, van der Woude CJ, Hansen BE, et al. Clinical and endosonographic effect of ciprofloxacin on the treatment of perianal fistulae in Crohn's disease with infliximab: a double-blind placebocontrolled study. Aliment Pharmacol Ther 2008; 20(11-12): 1329-36.
9. Maeda K, Okada M, Yao T, Sakurai T, et al. Intestinal and extraintestinal complications of Crohn's disease: predictors and cumulative probability of complications. J Gastroenterol 1994; 29(5): 577-82.
10. Sugita A, Koganei K, Harada H, et al. Surgery for Crohn's anal fistulas. J Gastroenterol 1995; 30 (Suppl 8): 143-46.
11. Schwartz DA, Loftus EV Jr, Tremaine WJ, et al. The natural history of fistulizing Crohn's disease in Olmsted County, Minnesota. Gastroenterology 2002; 122(4): 875-80.
12. Lapidus, A. Crohn's disease in Stockholm County during 1990-2001: an epidemiological update. World J Gastroenterol 2006; 12(1): 75-81.
13. Tang LY, Rawsthorne P, Bernstein CN. Are perineal and luminal fistulas associated in Crohn's disease? A population-based study. Clin Gastroenterol Hepatol 2006; 4(9): 1130-4.
14. Sandborn WJ, Fazio VW, Feagan BG, et al; American Gastroenterological Association Clinical Practice Committee. AGA technical review on perianal Crohn's disease. Gastroenterology 2003; 125(5): 1508-30.
15. Rahimi R, Nikfar S, Rezaie A, et al. A meta-analysis of broadspectrum antibiotic therapy in patients with active Crohn's disease. Clin Ther 2006; 28(12): 1983-8.
16. Sandborn WJ, Rutgeerts P, Enns R, et al. Adalimumab induction therapy for Crohn disease previously treated with infliximab: a randomized trial. Ann Intern Med 2007; 146(12): 829-38.
17. Jadad A. Randomised controlled trials. London, UK: BMJ Books 1998.
18. Rhodes J, Bainton D, Beck P, et al. Controlled trial of azathioprine in Crohn's disease. Lancet 1971; 2(7737): 1273-6.
19. Klein M, Binder H J, Mitchell M, et al. Treatment of Crohn's disease with azathioprine: a controlled evaluation. Gastroenterology 1974; 66(5): 916-22.
20. Present DH, Korelitz BI, Wisch N, et al. Treatment of Crohn's disease with 6-mercaptopurine. A long-term, randomized, doubleblind study. N Engl J Med 1980; 302(18): 981-7.
21. Present DH, Rutgeerts P, Targan S, et al. Infliximab for the treatment of fistulas in patients with Crohn's disease. N Engl J Med 1999; 340(18): 1398-405.
22. Sandborn WJ, Present DH, Isaacs KL, et al. Tacrolimus for the treatment of fistulas in patients with Crohn's disease: a randomized, placebo-controlled trial. Gastroenterology 2003; 125(2): 380-8.
23. Hart AL, Plamondon S, Kamm MA. Topical tacrolimus in the treatment of perianal Crohn's disease: exploratory randomized controlled trial. Inflamm Bowel Dis 2007; 13(3): 245-53.
24. Colombel JF, Schwartz DA, Sandborn WJ, et al. Adalimumab for the treatment of fistulas in patients with Crohn's disease. Gut 2009; 58(7): 940-8.
25. Thia KT, Mahadevan U, Feagan BG, et al. Ciprofloxacin or metronidazole for the treatment of perianal fistulas in patients with Crohn's disease: a randomized, double-blind, placebo-controlled pilot study. Inflamm Bowel Dis 2009; 15(1): 17-24.
26. Korzenik JR, Dieckgraefe BK, Valentine JF, et al; Sargramostim in Crohn's Disease Study Group. Sargramostim for active Crohn's disease. N Engl J Med 2005; 352(21): 2193-201.
27. Rezaie A, Taghavi Bayat B, Abdollahi M. Biologic management of fistulizing Crohn's disease. Int J Pharmacol 2005; 1(1):17-24.
28. Rahimi R, Nikfar S, Abdollahi M. Do anti-tumor necrosis factors induce response and remission in patients with acute refractory Crohn's disease? A systematic meta-analysis of controlled clinical trials. Biomed Pharmacother 2007; 61(1): 75-80.
29. Rahimi R, Nikfar S, Rahimi F, et al. A meta-analysis on the efficacy of probiotics for maintenance of remission and prevention of clinical and endoscopic relapse in Crohn's disease. Dig Dis Sci 2008; 53(9): 2524-31.
30. Kruis W. Review article: antibiotics and probiotics in inflammatory bowel disease. Aliment Pharmacol Ther 2008; 20(Suppl 4): 75-8.
31. Mow WS, Vasiliauskas EA, Lin YC, et al. Association of antibody responses to microbial antigens and complications of small bowel Crohn's disease. Gastroenterology 2004; 126(2): 414-24.
32. Sartor RB. Targeting enteric bacteria in treatment of inflammatory bowel diseases: why, how, and when. Curr Opin Gastroenterol 2003; 19358-365.
33. Colombel JF, Cortot A, van Kruiningen HJ. Antibiotics in Crohn's disease. Gut 2001; 48: 647.
34. Rosenberg JL, Levin B, Wall AJ, et al. A controlled trial of azathioprine in Crohn's disease. Am J Dig Dis 1975; 20(8): 721-6.
35. Peyrin-Biroulet L, Deltenre P, de Suray N, et al. Efficacy and safety of tumor necrosis factor antagonists in Crohn's disease: meta-analysis of placebo-controlled trials. Clin Gastroenterol Hepatol 2008; 6(6): 644-53.
36. Iida S, Kohno K, Yoshimura J, et al. Carbonic-adsorbent AST-120 reduces overload of indoxyl sulfate and the plasma level of TGFbeta1 in patients with chronic renal failure. Clin Exp Nephrol 2006; 10(4): 262-7.
37. Xu L, Kitani A, Fuss I, et al. Cutting edge: regulatory T cells induce CD4+CD25-Foxp3- T cells or are self-induced to become Th17 cells in the absence of exogenous TGF-β. J Immunol 2007; 178: 6725-9.
38. Rezaie A, Ghorbani F, Eshghtork A, et al. Alterations in salivary antioxidants, nitric oxide, and transforming growth factor-beta 1 in relation to disease activity in Crohn's disease patients. Ann N Y Acad Sci 2006; 1091: 110-22.